New pill showdown: can roflumilast beat methotrexate for psoriasis in private areas?
NCT ID NCT07543640
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two oral medications—roflumilast and methotrexate—for psoriasis in skin folds and genital areas, which are often hard to treat with creams alone. Fifty-six adults with topical-resistant psoriasis will take one of the two pills for 16 weeks. Researchers will measure how well each drug clears the rash and improves quality of life, aiming to find a more convenient treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Roflumilast (a daily pill) and methotrexate (a weekly pill)
- What this could lead to
- If roflumilast works well, it could offer a convenient oral treatment for hard-to-treat psoriasis in sensitive areas, with less need for frequent lab monitoring.
- What could go wrong
- This is a small, early-phase trial with only 56 people, so results may not apply to everyone. Roflumilast may not be more effective than methotrexate, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLEXURAL PSORIASIS (ALSO KNOWN AS INVERSE OR INTERTRIGINOUS PSORIASIS) AND GENITAL PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.